Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureCaili Xu, Xiaozhi Hu, Yanyang Nan, Zihan Dou, Wenjing Xue, Qinchao Hu, Xiting Huang, Xianxin Hua, Dianwen Ju, Xuyao Zhang
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Tumor-associated macrophages
10.1016/j.cub.2020.01.031 · 2020
Emerging phagocytosis checkpoints in cancer immunotherapy
10.1038/s41392-023-01365-z · 2023
The CD47-SIRPalpha Immune Checkpoint
10.1016/j.immuni.2020.04.011 · 2020
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
10.1016/j.cell.2009.05.046 · 2009
Targeting the CD47/SIRPalpha pathway in malignancies: recent progress, difficulties and future perspectives
2024
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPalpha pathway with high safety and preclinical efficacy for hematological and solid tumors
10.1186/s13045-025-01742-x · 2025
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
10.1056/nejmoa1807315 · 2018
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
10.1136/jitc-2022-005517 · 2022
Targeting phagocytosis checkpoints for cancer immunotherapy
10.1038/s41568-025-00893-w · 2026
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
10.1016/s1470-2045(21)00584-2 · 2021
SIRPalpha-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPalpha signal pathway via blocking the “don't eat me” signal and activating the “eat me” signal
10.1186/s13045-022-01385-2 · 2022
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
10.1073/pnas.1305569110 · 2013
CD47/SIRPalpha axis: bridging innate and adaptive immunity
10.1136/jitc-2022-004589 · 2022
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review
10.1136/jitc-2020-001408 · 2020
Deciphering the role of CD47 in cancer immunotherapy
10.1016/j.jare.2023.10.009 · 2024
Role of CD47 as a marker of self on red blood cells
10.1126/science.288.5473.2051 · 2000
Targeting CD47 for cancer immunotherapy
10.1186/s13045-021-01197-w · 2021
IgG4 anti-CD47: Erythrophagocytosis and potential transfusion complications
10.1111/trf.70111 · 2026
Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody)
10.1111/imj.15934 · 2022
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
10.1200/jco.18.02018 · 2019
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
10.1200/jco.22.02604 · 2023
Super-resolution microscopy unveils the nanoscale organization and self-limiting clustering of CD47 in human erythrocytes
10.1093/jmcb/mjae041 · 2025
Membrane mobility and clustering of Integrin Associated Protein (IAP, CD47)--major differences between mouse and man and implications for signaling
10.1016/j.bcmd.2006.01.012 · 2006
Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPalpha axis and a target for cancer immunotherapy
10.1038/s41591-019-0356-z · 2019
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
10.1073/pnas.1121623109 · 2012
Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPalpha Facilitate Apoptotic Cell Clearance by Macrophages
10.4049/jimmunol.1401719 · 2015
A CD47 antibody with minimized erythrocyte and thrombocyte toxicities
10.3389/fonc.2025.1686180 · 2025
A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
10.1158/1078-0432.ccr-25-1826 · 2025
TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties
10.1182/blood-2019-122793 · 2019
CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge
10.32604/or.2025.071708 · 2025
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
10.1016/j.apsb.2022.12.016 · 2023
Inhibition of the CD47-SIRPalpha axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data
10.3389/fimmu.2022.1027235 · 2022
Antigen Cross-Presentation by Macrophages
10.3389/fimmu.2020.01276 · 2020
CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity
10.1172/jci.insight.155022 · 2022
Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages
10.1016/1074-7613(95)90067-5 · 1995
Targeting the myeloid checkpoint receptor SIRPalpha potentiates innate and adaptive immune responses to promote anti-tumor activity
10.1186/s13045-020-00989-w · 2020
Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8(+) T cells
10.1002/cti2.70014 · 2024
IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy
10.1016/j.heliyon.2024.e39858 · 2024
Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma
10.2217/imt-2022-0087 · 2023
Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels
10.1038/nrendo.2012.254 · 2013
PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages
10.1186/s13046-022-02477-0 · doi-reference
PCSK9 Suppresses M2-Like Tumor-Associated Macrophage Polarization by Regulating the Secretion of OX40L from Hepatocellular Carcinoma Cells
10.1080/08820139.2022.2027439 · doi-reference
Diversity, Mechanisms, and Significance of Macrophage Plasticity
10.1146/annurev-pathmechdis-012418-012718 · doi-reference
Transcriptional regulation of macrophage polarization: enabling diversity with identity
10.1038/nri3088 · doi-reference
Protective and pathogenic functions of macrophage subsets
10.1038/nri3073 · doi-reference
The antitumor activities of anti-CD47 antibodies require Fc-FcgammaR interactions
10.1016/j.ccell.2023.10.007 · doi-reference
Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas
10.1182/blood.2019001744 · doi-reference
CD47-SIRPalpha blocking-based immunotherapy: Current and prospective therapeutic strategies
10.1002/ctm2.943 · doi-reference
Targeting CD47/SIRPalpha as a therapeutic strategy, where we are and where we are headed
10.1186/s40364-022-00373-5 · doi-reference
The landscape overview of CD47-based immunotherapy for hematological malignancies
10.1186/s40364-023-00456-x · doi-reference
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
10.3324/haematol.2024.286208 · doi-reference
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPalpha, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study
10.1186/s13045-024-01646-2 · doi-reference
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
10.1158/1078-0432.ccr-20-3706 · doi-reference
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer
10.1136/jitc-2024-010565 · doi-reference
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
10.1038/s41586-020-2911-7 · doi-reference
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials
10.1093/ehjcvp/pvad019 · doi-reference
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
10.1038/s41392-023-01690-3 · doi-reference